Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced preliminary first-quarter 2023 revenue estimates between $7.3 million and $7.8 million, marking the strongest results for the period since 2016. The company successfully placed 44 TheraClear®X devices, contributing to over 3,000 treatments sold since the product's launch in January 2023. Moreover, STRATA has converted 86 Pharos® accounts to XTRAC® devices, enhancing its presence in the eczema-laser market. CEO Bob Moccia expressed optimism about the sales momentum and its anticipated impact on revenues for 2023. The unaudited results are subject to revision, with full financial results expected in May 2023.
STRATA Skin Sciences, a medical technology firm, reported a record revenue of $36.2 million for 2022, up 21% from 2021, with fourth-quarter revenue at $10.6 million (17% increase year-over-year). Global recurring revenue reached $23 million for the year. Despite these gains, the company posted a net loss of $5.5 million for 2022 compared to a $2.7 million loss in 2021. The installed base of XTRAC® devices rose to 909. Looking forward, STRATA projects revenue in 2023 to be between $38 million and $40 million. The company aims to grow its market share while launching new marketing initiatives.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology firm focused on dermatologic treatments, will release its fourth-quarter 2022 financial results and Form 10-K on March 31, 2023. The company will hold a conference call at 8:30 AM EDT on the same day to discuss financial results and provide a corporate update. Key products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and the new TheraClear® X Acne Therapy System. STRATA operates a unique Partnership Program whereby practices are charged per treatment rather than for equipment purchases, ensuring support and marketing assistance.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced it will release its fourth quarter 2022 financial results on March 28, 2023, at 4:30 PM EDT. A conference call will be conducted to discuss the results and provide a corporate update. Interested parties can join the call using the numbers provided or view the webcast. STRATA specializes in products for treating dermatologic conditions such as psoriasis and acne.
STRATA Skin Sciences (NASDAQ: SSKN) has confirmed it has no financial ties or exposure to Silicon Valley Bank, stating that it does not hold cash deposits or securities with the bank. The company is focused on developing and marketing innovative dermatologic treatment technologies, including the XTRAC® and Pharos® lasers, as well as the TheraClear®X Acne Therapy System. STRATA utilizes a Partnership Program to provide in-office treatment options, emphasizing a service-oriented approach over traditional equipment purchases.